Condor Software Raises $24M in Series A to Expand Financial Intelligence Platform for Life Sciences

Decisions in biotech don’t fail loudly. They slip. Quietly. A number shows up late, a forecast drifts, a budget tightens at the wrong moment and suddenly a promising therapy is sitting in limbo, waiting on clarity that should’ve been there all along. Jennifer Kyle saw that pattern up close and decided ambiguity wasn’t a cost of doing business, it was the problem to solve.

Condor Software just pulled in $24M in Series A funding, led by Insight Partners with Felicis, 645 Ventures, Pamir Ventures, SNR Ventures, Prebys Ventures, and Bramalea Partners all leaning in. That’s not a casual nod. That’s conviction around a very specific pain that most people outside life sciences never see and insiders can’t unsee.

This is where Condor earns its name. When the financial fog rolls in, they don’t flap… they glide above it. An AI-powered financial intelligence platform built for life sciences, stitching together clinical, operational, and financial data in real time. Not next quarter. Not after reconciliation hell. Now.

Brice Wu, stepping in as Chief Product and Operations Officer, adds another layer of precision to the machine. You don’t bring in that kind of operator unless you’re planning to scale something that actually works.

And the numbers? They speak in a tone CFOs respect. Managing over $19B in R&D spend. Driving more than 90% forecast accuracy. Cutting month-end close times by 70%. Trimming budgets by 30% on average. That’s not optimization. That’s oxygen.

Customers like Acadia Pharmaceuticals, Alumis Therapeutics, BridgeBio Pharma, and Madrigal Pharmaceuticals aren’t experimenting here. They’re operationalizing clarity in an industry where uncertainty is the baseline.

The real play is hiding in plain sight. Pharma spends roughly $300B a year on R&D, and a shocking amount of it still runs on spreadsheets loosely held together across CRO portals and ERP systems. Condor didn’t invent the chaos. They’re just the first to treat it like a system problem instead of a staffing problem.

That’s the takeaway. The companies winning right now aren’t adding more people to chase complexity. They’re building infrastructure that makes complexity behave. Jennifer Kyle, Founder and CEO, and team didn’t just raise capital. They made a bet that financial intelligence is as critical to drug development as the science itself. And judging by who wrote the checks, the market is starting to agree.